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BACKGROUND
An elevated heart rate is an established marker of cardiovascular risk. Previous analy-
ses have suggested that ivabradine, a heart-rate–reducing agent, may improve out-
comes in patients with stable coronary artery disease, left ventricular dysfunction, 
and a heart rate of 70 beats per minute or more.
METHODS
We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, 
added to standard background therapy, in 19,102 patients who had both stable 
coronary artery disease without clinical heart failure and a heart rate of 70 beats per 
minute or more (including 12,049 patients with activity-limiting angina [class ≥II on 
the Canadian Cardiovascular Society scale, which ranges from I to IV, with higher 
classes indicating greater limitations on physical activity owing to angina]). We 
randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice 
daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per 
minute. The primary end point was a composite of death from cardiovascular 
causes or nonfatal myocardial infarction.
RESULTS
At 3 months, the mean (±SD) heart rate of the patients was 60.7±9.0 beats per min-
ute in the ivabradine group versus 70.6±10.1 beats per minute in the placebo group. 
After a median follow-up of 27.8 months, there was no significant difference be-
tween the ivabradine group and the placebo group in the incidence of the primary 
end point (6.8% and 6.4%, respectively; hazard ratio, 1.08; 95% confidence interval, 
0.96 to 1.20; P = 0.20), nor were there significant differences in the incidences of 
death from cardiovascular causes and nonfatal myocardial infarction. Ivabradine 
was associated with an increase in the incidence of the primary end point among 
patients with activity-limiting angina but not among those without activity-limiting 
angina (P = 0.02 for interaction). The incidence of bradycardia was higher with iv-
abradine than with placebo (18.0% vs. 2.3%, P<0.001).
CONCLUSIONS
Among patients who had stable coronary artery disease without clinical heart fail-
ure, the addition of ivabradine to standard background therapy to reduce the heart 
rate did not improve outcomes. (Funded by Servier; SIGNIFY Current Controlled 
Trials number, ISRCTN61576291.)
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A n elevated heart rate is estab-lished as a marker of cardiovascular risk in the general population and among pa-
tients with cardiovascular disease.1-5 Ivabradine 
inhibits the If (pacemaker) current in the sino-
atrial node6 and reduces the heart rate without 
affecting blood pressure or left ventricular sys-
tolic function. It has been shown to lessen symp-
toms and reduce ischemia in patients with stable 
angina pectoris.7,8 Ivabradine is known to im-
prove outcomes in patients with systolic heart 
failure.9 A trial of ivabradine involving patients 
with coronary artery disease and left ventricular 
systolic dysfunction did not show clinical bene-
fit,10 but post hoc analyses suggested that iv-
abradine improved outcomes in patients who had 
a heart rate of 70 beats per minute or more, par-
ticularly in those with angina.11 To confirm these 
findings, we conducted the Study Assessing the 
Morbidity–Mortality Benefits of the If Inhibitor 
Ivabradine in Patients with Coronary Artery Dis-
ease (SIGNIFY), a large, randomized, controlled 
trial of ivabradine involving patients who had 
stable coronary artery disease without clinical 
heart failure.
ME THODS
TRIAL DESIGN AND OVERSIGHT
We conducted this randomized, double-blind, 
parallel-group, placebo-controlled, event-driven 
study at 1139 centers in 51 countries. The study 
was designed to determine the effect of the addi-
tion of ivabradine to standard therapy in patients 
with stable coronary artery disease.12 The study 
protocol, available with the full text of this arti-
cle at NEJM.org, was approved by the ethics com-
mittee at each participating institution.
The trial was sponsored by Servier. The ex-
ecutive committee, which included nonvoting rep-
resentatives of the sponsor, was responsible for 
the study design, the interpretation of the results, 
the writing of the manuscript, and the decision to 
submit the manuscript for publication. The spon-
sor was responsible for data management. All 
the statistical analyses were performed by the 
Robertson Centre for Biostatistics at the Univer-
sity of Glasgow. The trial was overseen by an in-
dependent data monitoring committee. The ex-
ecutive committee had full access to the data and 
takes full responsibility for the accuracy and com-
pleteness of the data and analyses reported, as 
well as for the fidelity of this report to the trial 
protocol.
PARTICIPANTS
Eligible patients were at least 55 years of age and 
had documented and treated stable coronary ar-
tery disease but no evidence of clinical heart fail-
ure.12 Participants had to be in sinus rhythm, 
have a resting heart rate of 70 beats per minute 
or more on two consecutive electrocardiographic 
readings, and have at least one major adverse 
prognostic factor (angina pectoris of class ≥II on 
the Canadian Cardiovascular Society [CCS] scale, 
which ranges from I to IV, with higher classes 
indicating greater limitations on physical activity 
owing to angina; evidence of myocardial ische-
mia within the previous year; or hospital dis-
charge after a major coronary event within the 
previous year) or two minor adverse prognostic 
factors (a high-density lipoprotein cholesterol 
level <40 mg per deciliter [1 mmol per liter, ac-
cording to the study protocol] or a low-density 
lipoprotein cholesterol level >160 mg per deciliter 
[4 mmol per liter, according to the study proto-
col], despite lipid-lowering treatment; type 1 or 2 
diabetes mellitus; peripheral artery disease; cur-
rent smoking; or an age of ≥70 years). Patients 
with left ventricular dysfunction (left ventricular 
ejection fraction ≤40%) or an unstable cardiovas-
cular condition were excluded. Additional details 
of the selection, inclusion, and exclusion criteria 
are provided in Table S1 in the Supplementary 
Appendix, available at NEJM.org.
INTERVENTIONS AND ASSESSMENTS
After providing written informed consent, all the 
participants entered a 2-to-4-week placebo run-in 
phase to confirm eligibility and clinical stability. 
All the patients whose eligibility and clinical sta-
bility were confirmed and who had complied with 
taking the study drug during the run-in phase 
were randomly assigned by means of an interac-
tive voice-response or Web-response system to 
receive ivabradine at a dose of 7.5 mg twice daily 
or matching placebo (except for patients ≥75 years 
of age, who received 5.0 mg twice daily). Ran-
domization was stratified according to study cen-
ter and baseline status with respect to angina (no 
symptoms or CCS class I vs. CCS class ≥II). Patients 
and investigators were unaware of the treatment 
assignments.
In addition to the study drug, participants were 
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to receive stable background therapy according 
to contemporary guidelines (notably aspirin, 
statins, angiotensin-converting–enzyme [ACE] 
inhibitors [class I, level of evidence A in all 
guidelines], and beta-blockers [class I, level of 
evidence B in all guidelines]).13,14 The treating 
clinicians were given recommendations for ad-
justing the beta-blocker dose to achieve the 
greatest efficacy prior to the run-in phase and 
for keeping the dose constant thereafter.
Follow-up visits occurred at 1, 2, 3, and 6 months 
and every 6 months thereafter. The study-drug 
dose could be adjusted to 5.0, 7.5, or 10.0 mg twice 
daily, according to the heart rate as measured by 
electrocardiography at every visit (target heart rate, 
55 to 60 beats per minute) and symptoms of bra-
dycardia. If a patient was receiving the lowest dose, 
treatment was stopped if the heart rate was less 
than 45 beats per minute, if there was symptom-
atic bradycardia, or if they had a heart rate of less 
than 50 beats per minute that persisted at a newly 
scheduled control visit 1 week later.
END POINTS
The primary end point was a composite of death 
from cardiovascular causes or nonfatal myocar-
dial infarction. The secondary end points includ-
ed the components of the primary end point — 
death from cardiovascular causes and nonfatal 
myocardial infarction — as well as death from 
any cause. A description of all the secondary end 
points is provided in Table S2 in the Supplemen-
tary Appendix. Other variables assessed during 
the trial included heart rate (in all the patients) 
and change in angina symptoms (in patients 
with angina at baseline). All outcomes were adju-
dicated by an independent end-point validation 
committee.
STATISTICAL ANALYSIS
We estimated that we would need to enroll 16,850 
patients for the study to have 90% power to de-
tect an 18% reduction in the relative risk of the 
primary composite end point with ivabradine, as-
suming a 2.7% annual incidence with placebo 
and a mean follow-up period of 2.75 years, at a 
significance level of 5%. Additional details of the 
sample-size calculations are provided in the Sup-
plementary Appendix. During the trial, the data 
monitoring committee performed two planned 
interim analyses — after 35% and 60% of the 
anticipated number of primary end points had 
occurred. A P value of less than 0.001 was re-
quired for early termination due to benefit.
The baseline characteristics are shown ac-
cording to study group as means and standard 
deviations for continuous variables and as num-
bers and percentages for categorical variables. 
The efficacy analysis was based on the intention-
to-treat principle. A Cox proportional-hazards 
model was used to estimate the effect of study 
treatment on the primary end point and other 
time-to-event end points, with adjustment for 
the presence or absence of activity-limiting an-
gina pectoris (CCS class ≥II) at baseline. Results 
are presented as hazard ratios and 95% confi-
dence intervals with corresponding P values. 
Prespecified subgroup analyses were performed 
according to the presence or absence of activity-
limiting angina (CCS class ≥II) at baseline (the 
main subgroup analysis), as well as according to 
seven other prespecified subgroup variables. 
Time-to-event curves were prepared with the use 
of the Kaplan–Meier method. Adverse events were 
tabulated according to study group with appro-
priate P values (calculated with the use of the chi-
square test or Fisher’s exact test). The type I error 
was set at 5% (two-sided) for all statistical tests. 
SAS software, version 9.2 (SAS Institute), was used 
for statistical analyses.
R ESULT S
RANDOMIZATION AND FOLLOW-UP
Between October 12, 2009, and April 30, 2012, a 
total of 19,102 patients underwent randomiza-
tion; 9550 were assigned to ivabradine and 9552 
to placebo (Fig. S1 in the Supplementary Appen-
dix). The last patient visit occurred on January 24, 
2014. The median duration of follow-up was 27.8 
months (interquartile range, 21.0 to 35.2).
CHARACTERISTICS OF THE PARTICIPANTS
The two groups were well balanced with respect to 
baseline characteristics (Table 1). The mean age 
of the study population was 65 years, 72.4% of 
the patients were men, and the mean resting heart 
rate was 77.2 beats per minute. A total of 73.3% of 
the study population had had a previous myocar-
dial infarction, 67.8% had had previous coronary 
revascularization, and 63.1% had activity-limiting 
angina (CCS class ≥II). There was no evidence of 
left ventricular systolic dysfunction in the overall 
study population (mean ejection fraction, 56.4%).
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Most patients were receiving appropriate ther-
apy for cardiovascular disease (antiplatelet ther-
apy or anticoagulants in 97.7% of the patients, 
statins in 92.2%, beta-blockers in 83.1%, and ACE 
inhibitors in 59.3%). Details of beta-blocker use 
at baseline are shown in Table S3 in the Supple-
mentary Appendix. Patients with angina of CCS 
class II or higher were more likely than patients 
without angina or with CCS class I angina to have 
a history of myocardial infarction (75.3% vs. 
69.8%) and to be receiving beta-blockers (86.9% 
vs. 76.7%) and nitrates (49.5% vs. 23.8%) and 
were less likely to have undergone coronary re-
vascularization (61.1% vs. 79.3%) (Table S4 in 
the Supplementary Appendix).
STUDY-DRUG USE AND HEART RATE
The mean study-drug dose throughout the trial 
was 8.2±1.7 mg twice daily in the ivabradine 
group and 9.5±0.9 mg twice daily in the placebo 
group. At 3 months, the mean heart rate was re-
duced to 60.7±9.0 beats per minute with iv-
abradine and to 70.6±10.1 beats per minute with 
placebo (Fig. S2 in the Supplementary Appendix). 
The difference in the mean heart rate between 
the ivabradine group and the placebo group was 
maintained for the duration of the study in the 
total population and in the subgroups of patients 
with activity-limiting angina at baseline and 
those without angina at baseline (Fig. S2 in the 
Supplementary Appendix). The mean propor-
tion of patients who complied with taking the 
study drug (as assessed by means of pill counts) 
was 96.2±9.2% in the ivabradine group and 
96.6±8.3% in the placebo group.
The rates of permanent discontinuation of the 
study drug were 20.6% in the ivabradine group 
(1972 patients) and 14.5% in the placebo group 
(1384 patients). The main reason for study-drug 
withdrawal in the ivabradine group was asymp-
tomatic bradycardia (leading to withdrawal in 
272 patients, vs. 17 in the placebo group) and, to 
a lesser extent, symptomatic bradycardia (194 vs. 
33). Few patients changed the beta-blocker dose 
during the study, with 3.2% of the patients in 
the ivabradine group increasing the dose, 6.1% 
decreasing, and 3.5% stopping, as compared with 
5.8%, 3.7%, and 2.3%, respectively, in the placebo 
group (Table S3 in the Supplementary Appendix).
STUDY END POINTS
Results with respect to study end points are pre-
sented in Table 2 and Figure 1. There was no sig-
Table 1. Characteristics of the Study Population at Baseline.*
Characteristic
Ivabradine
(N = 9550)
Placebo
(N = 9552)
Age — yr 65.0±7.2 65.0±7.3
Body-mass index† 28.8±4.6 28.7±4.6
Heart rate — beats/min 77.1±6.9 77.2±7.1
Male sex — no. (%) 6949 (72.8) 6890 (72.1)
Race — no. (%)‡
White 7788 (81.5) 7745 (81.1)
Asian 1262 (13.2) 1285 (13.5)
Other 500 (5.2) 522 (5.5)
Blood pressure — mm Hg
Systolic 131±13 130±14
Diastolic 78±8 78±8
Cardiovascular risk factors and medical history
Duration of coronary artery disease — yr 6.2±6.3 6.1±6.2
Previous myocardial infarction — no. (%) 7009 (73.4) 6993 (73.2)
Previous coronary revascularization —  
no. (%)
6453 (67.6) 6496 (68.0)
Angina status — no. (%)
No symptoms 2400 (25.1) 2416 (25.3)
CCS class§
I 1113 (11.7) 1124 (11.8)
≥II 6037 (63.2) 6012 (62.9)
Dyslipidemia — no. (%) 6844 (71.7) 6853 (71.7)
Diabetes mellitus — no. (%) 4103 (43.0) 4127 (43.2)
Peripheral artery disease — no. (%) 1974 (20.7) 2042 (21.4)
Current smoker — no. (%) 2285 (23.9) 2320 (24.3)
Hypertension — no. (%) 8275 (86.6) 8191 (85.8)
Left ventricular ejection fraction — % 56.4±8.5 56.5±8.6
Previous stroke — no. (%) 634 (6.6) 631 (6.6)
Concomitant treatment — no. (%)
Antiplatelet agent or anticoagulant 9329 (97.7) 9343 (97.8)
Aspirin 8756 (91.7) 8736 (91.5)
Statin 8819 (92.3) 8791 (92.0)
Beta-blocker 7934 (83.1) 7944 (83.2)
ACE inhibitor 5719 (59.9) 5617 (58.8)
Angiotensin II–receptor blocker 2218 (23.2) 2255 (23.6)
Dihydropyridine calcium-channel 
blocker
2574 (27.0) 2544 (26.6)
Nitrate 3871 (40.5) 3770 (39.5)
Diltiazem or verapamil 438 (4.6) 403 (4.2)
Antidiabetic agent 3787 (39.7) 3799 (39.8)
* Plus–minus values are means ±SD. There were no significant differences (at 
P<0.05) between the study groups in any of the baseline characteristics. ACE 
denotes angiotensin-converting enzyme.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ Race was determined by the investigator during the patient’s interview.
§ Classes on the Canadian Cardiovascular Society (CCS) scale range from I to IV, 
with higher classes indicating greater limitations on physical activity owing to 
angina.
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nificant difference in the incidence of the pri-
mary end point between the ivabradine group 
and the placebo group (6.8% and 6.4%, respec-
tively; hazard ratio, 1.08; 95% confidence inter-
val [CI], 0.96 to 1.20; P = 0.20). There were also no 
significant differences between the two groups 
in the incidences of the components of the pri-
mary end point, death from cardiovascular causes 
(hazard ratio, 1.10; 95% CI, 0.94 to 1.28; P = 0.25) 
and nonfatal myocardial infarction (hazard ratio, 
1.04; 95% CI, 0.90 to 1.21; P = 0.60). The rate of 
death from any cause also did not differ signifi-
cantly between the two groups (hazard ratio, 1.06; 
95% CI, 0.94 to 1.21; P = 0.35). There was virtu-
ally no between-group difference in the incidence 
of sudden death (201 cases with ivabradine and 
202 with placebo). Finally, there were no signifi-
cant between-group differences in any other sec-
ondary end points.
SUBGROUP ANALYSES
There was a significant interaction between the 
study treatment and the presence of angina at 
baseline in the prespecified subgroup defined ac-
cording to CCS class (P = 0.02) (Fig. 2, and Table 
S5 in the Supplementary Appendix), but there was 
no significant interaction in the seven other pre-
specified subgroups (Fig. 2) or in an analysis per-
Table 2. Primary and Secondary End Points.*
End Point
Ivabradine
(N = 9550)
Placebo
(N = 9552)
Hazard Ratio 
(95% CI) P Value
no. of patients with event (%)
Primary composite end point: death from cardiovas-
cular causes or nonfatal myocardial  
infarction
654 (6.8) 611 (6.4) 1.08 (0.96–1.20) 0.20
Secondary end point
Death
Any cause 485 (5.1) 458 (4.8) 1.06 (0.94–1.21) 0.35
Cardiovascular causes 329 (3.4) 301 (3.2) 1.10 (0.94–1.28) 0.25
Coronary causes 263 (2.8) 249 (2.6) 1.06 (0.89–1.26) 0.52
Coronary revascularization
Any 562 (5.9) 564 (5.9) 1.00 (0.89–1.12) 0.98
Elective 270 (2.8) 305 (3.2) 0.89 (0.75–1.04) 0.15
Admission to hospital for heart failure 216 (2.3) 181 (1.9) 1.20 (0.99–1.46) 0.07
Myocardial infarction
Fatal or nonfatal 392 (4.1) 372 (3.9) 1.06 (0.92–1.22) 0.43
Nonfatal 351 (3.7) 339 (3.5) 1.04 (0.90–1.21) 0.60
Fatal or nonfatal myocardial infarction or 
coronary revascularization
718 (7.5) 739 (7.7) 0.97 (0.88–1.08) 0.59
Fatal or nonfatal myocardial infarction, coronary 
revascularization, or unstable angina
766 (8.0) 782 (8.2) 0.98 (0.89–1.08) 0.70
Death from cardiovascular causes, nonfatal  
myocardial infarction, or nonfatal stroke
774 (8.1) 731 (7.7) 1.06 (0.96–1.18) 0.22
Death from coronary causes or nonfatal  
myocardial infarction
590 (6.2) 562 (5.9) 1.05 (0.94–1.18) 0.37
Nonfatal myocardial infarction, coronary  
revascularization, or unstable angina
734 (7.7) 759 (7.9) 0.97 (0.87–1.07) 0.53
* Estimates were based on a Cox proportional-hazards model, with adjustment for the presence or absence of angina 
pectoris (CCS class ≥II) at baseline. Death from coronary causes included death due to heart failure, death due to myo-
cardial infarction, death related to a coronary-artery procedure, death from presumed arrhythmia, and sudden death of 
unknown cause. Death from cardiovascular causes included all deaths from coronary causes, death related to cardio-
vascular procedures other than coronary-artery procedures, fatal stroke, other deaths from cardiovascular causes, non-
sudden death of unknown cause, and unclassifiable deaths. CI denotes confidence interval.
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formed according to country of origin (data not 
shown). Ivabradine was associated with an in-
crease in the incidence of the primary end point 
among patients who had angina of CCS class II 
or higher (7.6%, vs. 6.5% with placebo; hazard 
ratio, 1.18; 95% CI, 1.03 to 1.35; P = 0.02) but not 
among patients without angina or those who had 
angina of class I (hazard ratio, 0.89; 95% CI, 0.74 
to 1.08; P = 0.25) (Table S5 and Fig. S3 in the Sup-
plementary Appendix). The effect of ivabradine 
among patients with angina of CCS class II or 
higher appeared to be consistent between the 
two components of the primary end point (haz-
ard ratio for death from cardiovascular causes, 
1.16; 95% CI, 0.97 to 1.40; P = 0.11; and hazard 
ratio for nonfatal myocardial infarction, 1.18; 
95% CI, 0.97 to 1.42; P = 0.09). In the subgroup of 
patients with angina of CCS class II or higher, 
1446 patients in the ivabradine group (24.0%) 
had an improvement in the CCS angina class at 
3 months, as compared with 1131 in the placebo 
group (18.8%) (P = 0.01).
ADVERSE EVENTS
Adverse events during the study occurred in 
73.3% of the patients in the ivabradine group and 
in 66.9% of those in the placebo group (P<0.001) 
(Table 3). Ivabradine increased the frequency of 
symptomatic bradycardia (7.9%, vs. 1.2% with 
placebo), asymptomatic bradycardia (11.0% vs. 
1.3%), atrial fibrillation (5.3% vs. 3.8%), and phos-
phenes (5.4% vs. 0.5%) (P<0.001 for all compari-
sons). A serious adverse event occurred during 
the study in 3588 patients in the ivabradine group 
(37.6%) and in 3375 in the placebo group (35.4%) 
(P = 0.001) (Table S6 in the Supplementary Ap-
pendix). These events were classified as cardiac 
disorders in 19.0% and 16.7% of the patients, 
respectively. Adverse events led to study-drug with-
drawal in 13.2% of the patients in the ivabradine 
group and in 7.4% of those in the placebo group 
(P<0.001) (Table S7 in the Supplementary Appen-
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Figure 1. Kaplan–Meier Plots of the Primary Composite 
End Point and Its Components.
The primary end point was a composite of death from 
cardiovascular causes or nonfatal myocardial infarction 
The insets show the same data on an enlarged y axis. 
CI denotes confidence interval.
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dix). Safety data for the angina subgroups are 
presented in Tables S6, S7, and S8 in the Supple-
mentary Appendix.
DISCUSSION
Our study evaluated the use of ivabradine, added 
to background guideline-based medical treatment, 
in patients who had stable coronary artery dis-
ease without clinical heart failure. We found no 
benefit of ivabradine in reducing the risk of car-
diovascular events.
Previous observational studies have shown 
that an elevated heart rate is associated with an 
increased risk of cardiovascular events in popu-
lations with stable coronary artery disease.2-4,15,16 
The lack of benefit of ivabradine in SIGNIFY con-
trasts with results from previous post hoc analy-
ses with this agent suggesting that it would im-
prove outcomes in patients with stable coronary 
artery disease.10,11 In addition, in patients with 
heart failure, the reduction in heart rate with 
ivabradine has been shown to improve clinical 
outcomes, beyond the improvements observed 
with beta-blockers.9,17
Although the study population in SIGNIFY had 
a high prevalence of risk factors owing to the 
inclusion criteria, the annual incidence of the 
primary end point was relatively low (approxi-
mately 2.8%), probably owing to the background 
therapy the patients were receiving, which was 
administered according to current guidelines. 
Treatment with ivabradine had the intended ef-
fect on heart rate, with a between-group differ-
ence of approximately 10 beats per minute. The 
incidences of bradycardia and atrial fibrillation 
1.0 2.0
Placebo BetterIvabradine Better
Angina class at baseline
Class I or no symptoms
Class ≥II
Beta-blocker use at randomization
Yes
No
Heart rate
<75 beats/min
≥75 beats/min
Age
<65 yr
≥65 yr
Sex
Male
Female
History of diabetes
Yes
No
Previous myocardial infarction
Yes
No
Previous coronary revascularization
Yes
No
Ivabradine
No. of
Patients Hazard Ratio (95% CI)PlaceboSubgroup
0.89 (0.74–1.08)
1.11 (0.93–1.32)
1.05 (0.92–1.21)
1.07 (0.94–1.21)
1.10 (0.86–1.41)
1.06 (0.91–1.24)
1.09 (0.93–1.27)
1.16 (0.93–1.44)
1.05 (0.92–1.19)
1.02 (0.88–1.19)
1.14 (0.97–1.34)
1.05 (0.91–1.22)
1.10 (0.93–1.30)
1.07 (0.82–1.40)
1.08 (0.95–1.21)
0.5
1.18 (1.03–1.35)
P Value for
Interaction
195/3513 (5.6)
459/6037 (7.6)
543/7934 (6.8)
111/1616 (6.9)
289/4589 (6.3)
365/4960 (7.4)
309/5109 (6.1)
345/4441 (7.8)
485/6949 (7.0)
169/2601 (6.5)
324/4103 (7.9)
330/5447 (6.1)
519/7009 (7.4)
135/2541 (5.3)
397/6453 (6.2)
257/3097 (8.3)
221/3540 (6.2)
390/6012 (6.5)
506/7944 (6.4)
105/1608 (6.5)
263/4581 (5.7)
348/4971 (7.0)
272/5096 (5.3)
339/4456 (7.6)
460/6890 (6.7)
151/2662 (5.7)
301/4127 (7.3)
310/5425 (5.7)
487/6993 (7.0)
124/2559 (4.9)
380/6496 (5.8)
231/3056 (7.6)
7,053
12,049
15,878
3,224
9,170
9,931
10,205
8,897
13,839
5,263
8,230
10,872
14,002
5,100
12,949
6,153
0.02
0.98
0.69
0.35
0.46
0.83
0.84
0.66
no. of events/total no. (%)
Figure 2. Forest Plot of the Primary Composite End Point in Prespecified Subgroups.
The data are the numbers and proportions of patients with a first event. Estimates are based on a Cox proportional-hazards model, with 
adjustment for the presence or absence of angina at baseline (class ≥II on the Canadian Cardiovascular Society scale, which ranges from 
I to IV, with higher classes indicating greater limitations on physical activity owing to angina).
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were higher with ivabradine than with placebo. 
Bradycardia occurred more often in SIGNIFY than 
in previous ivabradine trials, most likely owing 
to the dose regimen in SIGNIFY, which included 
higher initiation and maintenance doses than 
those that are currently recommended.
There are a number of hypotheses to explain 
the lack of a benefit in SIGNIFY. It is possible 
that ivabradine decreased the heart rate too 
much or that there may be a J-shaped curve for 
the relationship between heart rate and out-
come. Ivabradine may have unintended effects 
(e.g., adjustment of the doses of other heart-
rate–lowering agents) that may have affected the 
potential benefits of the lowering of heart rate 
with ivabradine. However, the use and dosing of 
beta-blockers after randomization differed only 
slightly between patients who received ivabradine 
and those who received placebo.
It is also possible that heart-rate–reducing 
antianginal agents have no effect on outcomes 
in patients with stable coronary artery disease. 
Although there is historical evidence of a benefit 
of beta-blockers after myocardial infarction, there 
is little current evidence of their benefit with 
respect to hard clinical outcomes in patients 
who have stable coronary artery disease without 
left ventricular dysfunction. In fact, a recent ob-
servational analysis has suggested the oppo-
site.18 This contrasts with the results of trials 
testing the effects of beta-blockers or ivabradine 
in patients with systolic heart failure, including 
those with heart failure of ischemic origin.9,19
The benefit observed with lowering the heart 
rate in patients with heart failure but not in 
those with stable coronary artery disease may 
reflect the fact that an elevated heart rate is due 
to different pathophysiological mechanisms in 
these two conditions.1 In patients with heart fail-
ure, there is neurohormonal activation, which in 
itself leads to ventricular remodeling, further left 
ventricular dysfunction, and a vicious cycle of 
decline. In contrast, there is no neurohormonal 
activation in stable coronary artery disease with-
out left ventricular dysfunction.
There was a significant interaction between 
Table 3. Adverse Events during the Study.*
Event
Ivabradine
(N = 9539)
Placebo
(N = 9544) P Value
no. of patients with event (%)
Any adverse event 6990 (73.3) 6382 (66.9) <0.001
Selected adverse events†
Bradycardia 1718 (18.0) 223 (2.3) <0.001
Symptomatic 757 (7.9) 110 (1.2) <0.001
Asymptomatic 1047 (11.0) 126 (1.3) <0.001
Phosphenes 512 (5.4) 52 (0.5) <0.001
Blurred vision 117 (1.2) 37 (0.4) <0.001
Atrioventricular block
Second degree 44 (0.5) 31 (0.3) 0.13
Third degree 20 (0.2) 19 (0.2) 0.87
Atrial fibrillation 508 (5.3) 362 (3.8) <0.001
QT-interval prolongation‡ 171 (1.8) 65 (0.7) <0.001
Supraventricular tachyarrhythmia 137 (1.4) 113 (1.2) 0.13
Immune disorder 22 (0.2) 28 (0.3) 0.40
Severe ventricular arrhythmia 79 (0.8) 66 (0.7) 0.28
* The incidence of adverse events is provided for all the patients who had at least one dose of study drug. Patients may 
have had more than one type of adverse event (including symptomatic and asymptomatic bradycardia).
† Selected adverse events were those listed in the risk-management plan for ivabradine.
‡ Data include prolongation of the corrected QT interval and uncorrected QT interval as assessed by means of electrocar-
diography.
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the effect of ivabradine and the presence of angina 
(CCS class ≥II) at baseline. In that subgroup, 
ivabradine increased the absolute risk of the 
primary composite end point of death from car-
diovascular causes or nonfatal myocardial infarc-
tion by 1.1 percentage points. The explanation for 
this surprising finding is uncertain, although it 
should be treated with caution since the results of 
the primary efficacy analysis were not significant.
In conclusion, the results of SIGNIFY show 
that ivabradine, added to guideline-recommend-
ed medical therapy, did not improve the outcome 
in patients who had stable coronary artery disease 
without clinical heart failure. There is a signal for 
an increase in the risk of cardiovascular events 
among patients with angina of CCS class II or 
higher. Given that the primary cardiovascular 
effect of ivabradine is to reduce heart rate, these 
results suggest that an elevated heart rate is only 
a marker of risk — but not a modifiable deter-
minant of outcomes — in patients who have 
stable coronary artery disease without clinical 
heart failure.
Supported by Servier.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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